2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
India successfully achieves 56 auctions of critical ...
India needs to strengthen its position as global pha...
FIIs stood as net buyers in equities as per June 23 ...
Perspective on performance outlook of Gold and India...
The Future of Fabrics: From Natural Fibers to Bio-En...
China Expands Automotive After-Market Sector to Boos...
South Africa Economy Update 23rd June 2026 by CareEd...
Shashi Tharoor-led External Affairs Committee reache...
US-Iran deal, current crude levels will support rupe...
US Trade Delegation led by Sergio Gor reaches Vanijy...
